Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/4/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. GWRE
10. CIEN

Go back to Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

Y-mAbs Therapeutics (YMAB) PT Lowered to $7 at Morgan Stanley

March 4, 2025 4:37 PM EST

Morgan Stanley analyst Michael Ulz lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $7.00 (from $11.00) while maintaining a Underweight rating.

The analyst comments "2024 revenues were previously announced, while 2025 sales guidance disappoints, implying a y/y decline as Danyelza continues to face challenges. Following... More

Y-mAbs Therapeutics (YMAB) PT Lowered to $12 at BofA Securities

March 4, 2025 12:54 PM EST

BofA Securities analyst Alec Stranahan lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $12.00 (from $14.00) while maintaining a Neutral rating.

The analyst comments "YMAB shares are trading -7.3% (NBI: +0.1%) after sharing updates which focused on guidance for 2025 and reiterating corporate priorities including the... More

Y-mAbs Therapeutics (YMAB) PT Lowered to $18 at Clear Street

March 4, 2025 10:16 AM EST

Clear Street analyst Bill Maughan lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $18.00 (from $21.00) while maintaining a Buy rating.

The analyst comments "YMAB is trading down (-12%, XBI -1%) after announcing 4Q/FY24 results and 2025 guidance this morning. Revenues were... More